Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW | Zendy

Matthew J. Grigg | Zendy; Timothy William | Zendy; Bridget E. Barber | Zendy; Giri Shan Rajahram | Zendy; Jayaram Me | Zendy; Emma Schimann | Zendy; Christopher S. Wilkes | Zendy; Kaajal Patel | Zendy; Arjun Chandna | Zendy; Ric N. Price | Zendy; Tsin Wen Yeo | Zendy; Nicholas M. Anstey | Zendy

Open Access

Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW

Author(s) -

Matthew J. Grigg,

Timothy William,

Bridget E. Barber,

Giri Shan Rajahram,

Jayaram Me,

Emma Schimann,

Christopher S. Wilkes,

Kaajal Patel,

Arjun Chandna,

Ric N. Price,

Tsin Wen Yeo,

Nicholas M. Anstey

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix779

Subject(s) - medicine , artemether , plasmodium knowlesi , artemether/lumefantrine , lumefantrine , malaria , randomized controlled trial , parasitemia , confidence interval , plasmodium falciparum , artemisinin , chloroquine , gastroenterology , immunology , plasmodium vivax

Plasmodium knowlesi is reported increasingly across Southeast Asia and is the most common cause of malaria in Malaysia. No randomized trials have assessed the comparative efficacy of artemether-lumefantrine (AL) for knowlesi malaria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research